TXG
NASDAQ10x Genomics Inc.
Price$21.43+0.10 (+0.47%)
01:30 PM07:45 PM
News · 26 weeks47-60%
2025-10-262026-04-19
Mix2290d
- Insider10(45%)
- Other7(32%)
- Earnings2(9%)
- SEC Filings2(9%)
- Analyst1(5%)
Latest news
25 items- PR10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and UnderstoodEnables Whole-Transcriptome In Situ Spatial Biology with Single-Cell Sensitivity at ScaleDebuts at AACR Annual Meeting 2026 with Data from Leading Research Institutions, Including the June Lab at the Perelman School of Medicine, University of Pennsylvania and German Cancer Research Institute (DKFZ)PLEASANTON, Calif., April 18, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced Atera, a new in situ spatial biology platform engineered to deliver whole-transcriptome spatial analysis with single-cell sensitivity at unprecedented scale.
- INSIDERSEC Form 4 filed by Saxonov Serge4 - 10x Genomics, Inc. (0001770787) (Issuer)
- PR10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026PLEASANTON, Calif., April 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2026 after market close on Thursday, May 7, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's
- ANALYST10x Genomics upgraded by William BlairWilliam Blair upgraded 10x Genomics from Mkt Perform to Outperform
- INSIDERSEC Form 4 filed by Saxonov Serge4 - 10x Genomics, Inc. (0001770787) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
- PRBioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical LabsThe global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in scale over existing data available in the world todayThe Launch of STELA: Bioptimus is establishing the largest clinically linked multimodal atlas, starting in oncology and immunology tissue, designed to generate harmonized multi-omics patient data.A Strategic Partnership with 10x Genomics: Leveraging the Xenium spatial transcriptomics platform as the foundational partner for the launch, the initiative sets a new benchmark for reproducible, AI-ready data generation across leading research institutions worldwide.A Strategic Partnership with the
- SECAmendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
- PRPerturbAI Launches from Stealth, Unveils the World's Largest In Vivo CRISPR Atlas- Fueled by best-in-class technology and deep expertise in genome engineering and AI, PerturbAI is uniquely positioned to redefine therapeutic discovery, making it more scalable, translatable and cost-efficient - - Dataset of 8 million brain-wide cells, generated and analyzed in collaboration with NVIDIA, Allen Institute for Brain Science and 10x Genomics, establishes the largest causal map of gene function in living tissue, showcasing the power of PerturbAI's scalable discovery engine -SAN FRANCISCO, March 17, 2026 /PRNewswire/ -- PerturbAI, an AI-native therapeutics company accelerating drug discovery through systems-level understanding of diseases, emerged from stealth today with the publ
- SECAmendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
- INSIDERChief Executive Officer Saxonov Serge gifted 2,750 shares and sold $367,097 worth of shares (16,152 units at $22.73), decreasing direct ownership by 2% to 1,200,917 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDERChief Executive Officer Saxonov Serge was granted 157,895 shares, increasing direct ownership by 15% to 1,219,819 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDEROfficer Hindson Benjamin J. was granted 88,816 shares, increasing direct ownership by 21% to 513,595 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDERChief Financial Officer Taich Adam was granted 106,579 shares, increasing direct ownership by 37% to 394,996 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDERDirector Teichmann Sarah A. sold $147,108 worth of shares (7,579 units at $19.41), decreasing direct ownership by 22% to 26,780 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDERChief Executive Officer Saxonov Serge sold $178,928 worth of shares (9,632 units at $18.58), decreasing direct ownership by 0.90% to 1,061,924 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDERChief Financial Officer Taich Adam sold $166,593 worth of shares (8,968 units at $18.58), decreasing direct ownership by 3% to 288,417 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDEROfficer Hindson Benjamin J. sold $145,379 worth of shares (7,826 units at $18.58), decreasing direct ownership by 2% to 424,779 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- PR10x Genomics to Participate in the 46th Annual TD Cowen Health Care ConferencePLEASANTON, Calif., Feb. 19, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, at 11:50 a.m. Eastern Time. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event.About 10x Genomics10
- SECSEC Form S-8 filed by 10x Genomics Inc.S-8 - 10x Genomics, Inc. (0001770787) (Filer)
- SEC10x Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - 10x Genomics, Inc. (0001770787) (Filer)
- PR10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026PLEASANTON, Calif., Feb. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided its outlook for 2026. Recent Updates Revenue was $166.0 million for the fourth quarter of 2025, representing a 1% increase over the corresponding period of 2024. Revenue was $642.8 million for the full year of 2025. Excluding $44.1 million of non-recurring revenue related to patent litigation settlements, full-year revenue was $598.7 million, rep
- PR10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026PLEASANTON, Calif., Jan. 22, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Thursday, February 12, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.
- SEC10x Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - 10x Genomics, Inc. (0001770787) (Filer)
- PR10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune DiseaseStudy aims to identify single cell immune signatures of disease activity and treatment response to support clinical care PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced a collaboration with Brigham & Women's Hospital, a world-class academic medical center, to analyze peripheral blood samples from patients living with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and giant cell arteritis (GCA) to uncover immune signatures associated with disease activity, flare, remission and therapeutic response.